Innoviva Past Earnings Performance
Past criteria checks 2/6
Innoviva's earnings have been declining at an average annual rate of -12.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 1.8% per year. Innoviva's return on equity is 9.7%, and it has net margins of 18.3%.
Key information
-12.5%
Earnings growth rate
-1.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 1.8% |
| Return on equity | 9.7% |
| Net Margin | 18.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price
Jul 26
Innoviva: Potentially Overvalued
Jun 21Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems
May 21Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Feb 05Is Innoviva (NASDAQ:INVA) A Risky Investment?
Nov 04Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly
Mar 02Innoviva Stock? Not Yet. Short Puts? Definitely.
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Jun 16Continuing To Avoid Innoviva Inc.
Jun 07We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
Mar 04Taking Innoviva Winnings Off The Table, Again
Feb 21Innoviva Inc.: Short Puts Are Compelling
Jan 15Is Innoviva (NASDAQ:INVA) A Risky Investment?
Oct 19Taking Profits In Innoviva Inc.
Oct 16Innoviva reports Q1 results
Apr 28These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Mar 30Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 04Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?
Jan 15These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Dec 25
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?
Dec 04Innoviva: Only For Short-Term Traders
Nov 04Innoviva reports Q3 results
Oct 28Revenue & Expenses Breakdown
How Innoviva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 353 | 65 | 111 | -21 |
| 30 Jun 24 | 330 | 145 | 113 | 0 |
| 31 Mar 24 | 312 | 181 | 109 | 0 |
| 31 Dec 23 | 310 | 180 | 98 | 0 |
| 30 Sep 23 | 290 | 50 | 84 | 31 |
| 30 Jun 23 | 290 | 233 | 83 | 0 |
| 31 Mar 23 | 318 | 233 | 71 | 0 |
| 31 Dec 22 | 331 | 214 | 58 | 0 |
| 30 Sep 22 | 373 | 293 | 46 | 0 |
| 30 Jun 22 | 404 | 99 | 21 | 0 |
| 31 Mar 22 | 396 | 188 | 13 | 0 |
| 31 Dec 21 | 392 | 266 | 16 | 0 |
| 30 Sep 21 | 375 | 309 | 17 | 0 |
| 30 Jun 21 | 365 | 265 | 17 | 0 |
| 31 Mar 21 | 344 | 253 | 16 | 0 |
| 31 Dec 20 | 337 | 224 | 12 | 0 |
| 30 Sep 20 | 322 | 216 | 8 | 0 |
| 30 Jun 20 | 299 | 228 | 9 | 0 |
| 31 Mar 20 | 285 | 189 | 11 | 0 |
| 31 Dec 19 | 261 | 157 | 15 | 0 |
| 30 Sep 19 | 265 | 375 | 17 | 0 |
| 30 Jun 19 | 261 | 382 | 13 | 0 |
| 31 Mar 19 | 264 | 399 | 13 | 0 |
| 31 Dec 18 | 261 | 395 | 19 | 0 |
| 30 Sep 18 | 251 | 190 | 17 | 0 |
| 30 Jun 18 | 238 | 166 | 24 | 0 |
| 31 Mar 18 | 229 | 147 | 30 | 0 |
| 31 Dec 17 | 217 | 134 | 32 | 0 |
| 30 Sep 17 | 191 | 101 | 35 | 0 |
| 30 Jun 17 | 176 | 92 | 32 | 0 |
| 31 Mar 17 | 150 | 72 | 28 | 0 |
| 31 Dec 16 | 134 | 60 | 23 | 0 |
| 30 Sep 16 | 113 | 38 | 22 | 0 |
| 30 Jun 16 | 93 | 19 | 22 | 0 |
| 31 Mar 16 | 71 | -4 | 21 | 0 |
| 31 Dec 15 | 54 | -19 | 20 | 0 |
| 30 Sep 15 | 38 | -39 | 21 | 0 |
| 30 Jun 15 | 26 | -56 | 25 | 0 |
| 31 Mar 15 | 16 | -68 | 29 | 0 |
| 31 Dec 14 | 8 | -74 | 35 | 0 |
| 30 Sep 14 | 3 | -66 | 35 | 0 |
| 30 Jun 14 | 2 | -55 | 32 | 0 |
| 31 Mar 14 | 2 | -9 | 27 | 0 |
| 31 Dec 13 | 5 | -31 | 24 | 0 |
Quality Earnings: INVA has a large one-off loss of $98.4M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: INVA's current net profit margins (18.3%) are higher than last year (17.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INVA's earnings have declined by 12.5% per year over the past 5 years.
Accelerating Growth: INVA's earnings growth over the past year (29.5%) exceeds its 5-year average (-12.5% per year).
Earnings vs Industry: INVA earnings growth over the past year (29.5%) did not outperform the Pharmaceuticals industry 54.6%.
Return on Equity
High ROE: INVA's Return on Equity (9.7%) is considered low.